KFSH unveils AI ECG platform for earlier heart failure detection

King Faisal Specialist Hospital & Research Centre is presenting CardioScope at HLTH Europe 2026 in Amsterdam, an AI-powered ECG platform designed to spot left ventricular systolic dysfunction earlier and support faster clinical decisions. The project aims to turn a low-cost, widely available test into a scalable screening tool for earlier intervention and better use of healthcare resources.

Why it matters: - CardioScope is aimed at finding left ventricular systolic dysfunction before heart failure becomes clinically obvious. - Earlier detection could help clinicians intervene before irreversible myocardial damage develops. - The platform uses ECGs, which are faster, more accessible and lower cost than echocardiography, making broader screening more realistic.

What happened: - King Faisal Specialist Hospital & Research Centre is presenting its AI-powered electrocardiography work at HLTH Europe 2026 in Amsterdam, which runs June 15-18. - The project, called CardioScope, uses AI-enabled ECG analysis to support early detection of cardiac dysfunction and faster clinical decision-making. - KFSH developed a deep-learning model inside a secure, clinician-facing software platform.

The details: - CardioScope is designed as a scalable digital biomarker for detecting left ventricular systolic dysfunction. - The platform is built to provide real-time, non-invasive decision support. - KFSH says multi-center validation underpins the platform’s development. - The intended benefits include fewer diagnostic delays, better use of healthcare resources and improved patient outcomes. - KFSH says the platform is flexible enough to serve as a digital biomarker engine for cardiovascular and systemic diseases beyond heart failure prevention. - The work fits KFSH’s precision medicine strategy, which uses advanced data models to support earlier diagnosis, personalized care and more efficient clinical pathways. - The project also ties into KFSH’s applied AI ecosystem led by the Centre for Healthcare Intelligence. - That center has supported locally developed AI applications in medical image analysis, patient-flow management, resource optimization and patient-experience enhancement.

Between the lines: - The CardioScope effort suggests KFSH is pushing AI from experimental research toward clinical workflow tools. - The focus on a common, low-cost test points to a strategy of scaling screening rather than relying only on specialized imaging. - By framing the platform as a digital biomarker engine, KFSH is signaling broader ambitions than one disease area. - The HLTH Europe appearance also places the hospital in wider discussions about responsible AI and digital health adoption.

What's next: - KFSH is positioning CardioScope for broader clinical use if validation and deployment continue to progress. - The hospital is likely to keep linking the platform to its larger AI and precision medicine programs. - Wider adoption would depend on how well the system performs across settings and patient groups.

The bottom line: - KFSH is trying to turn a routine ECG into an earlier warning system for heart failure and a platform for broader AI-driven care.